

## Remarks

Applicant hereby elects without traverse to prosecute in this application the subject matter of Group I, claims 1-6, 8-11, 32, 33 and 39 drawn to an isolated nucleic acid, probe, vector and host cell. Applicants reserve the right to prosecute any subject matter not examined here in one or more divisional application(s).

Regarding the additional restriction requirement for a sequence election, Applicant hereby elects with traverse to prosecute in this application the sequence of SEQ ID NO: 1.

Regarding the traversal Applicant respectfully points out that the SEQ ID NOS: 1, 2, 3, 4 and 8 which are referenced in elected Group I (claims 1-6, 8-11, 32, 33 & 39) are all closely related. SEQ ID NO: 1 is the full length RGL3 cDNA. SEQ ID NO: 2 is the open reading frame portion of the same RGL3 cDNA. SEQ ID NO: 3 is the amino acid sequence of the full length RGL3 protein encoded by the nucleotide sequence of NO: 1. Finally, SEQ ID NO: 4 is a portion (nt 964 – 1023) of the nucleotide sequence of NO: 1. In view of the above, Applicant submits that although it may now be customary for Group 1631 to limit examination to one sequence, it should not constitute an undue burden, in fact, for the Examiner to consider all four of the closely related sequences of Group I together.


### **Sequence Compliance**

Applicant has added new sequences numbered 54 through 68 to incorporate the sequences identified in Figure 1B, Figure 1C, and Figure 1D. Per the Examiner's instructions, Applicant has amended the Brief Description of the Drawings section in the specification to insert the corresponding sequence identification numbers. Due to the need to list the additional sequences, Applicant submits herewith a new CD-ROM containing the revised "Sequence Listing" and two computer readable form "Sequence Listing" copies along with the required statements under 37 CFR § 1.821 (f) and (g). Applicant respectfully requests that the revised "Sequence Listing" submitted herewith replace the original "Sequence Listing" as filed.

Applicant has additionally revised Figure 1B, Figure 1C, and Figure 1D to insert the corresponding sequence identification numbers. Appended hereto is a copy of Figure 1B, Figure 1C, and Figure 1D labeled "Annotated Sheet Showing Changes" whereon the sequence identification numbers are inserted in red ink. Additionally, appended hereto is a revised Figure 1B, Figure 1C, and Figure 1D labeled "Replacement Sheet" whereon the sequence identification numbers are properly printed. Applicant respectfully requests that the Examiner accept the changes to the drawing figures and enter same.

Early and favorable action is earnestly solicited.

Respectfully submitted,

  
Yonggang Ji  
Registration No.: 53,073  
Agent for Applicants

Amersham Biosciences Corp  
800 Centennial Avenue  
P. O. Box 1327  
Piscataway, New Jersey 08855-1327

Tel: (732) 980-2875  
Fax: (732) 457-8463

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on August 6, 2003.

Signature: \_\_\_\_\_

Name: \_\_\_\_\_

Melissa Leck